

2

PATENT
DOCKET NO. 329368-101A
SERIAL NO. 08/854,825

At page 6, lines 26-27, strike "SEQ ID NO:55" and substitute therefor -- E1₂₅₇₋₂₆₆;
SEQ ID NO:3 --.

At page 8, line 36, strike "SEQ ID NO:55" and substitute therefor -- E1₂₅₇₋₂₆₆; SEQ ID
NO:3 --.

At page 9, line 26, after "acids", insert -- or to less than about 50 amino acids --.

At page 11, line 14, strike "aryl" and substitute therefor -- aralkyl --.

At page 16, line 17, strike "SEQ ID NO:55" and substitute therefor -- E1₂₅₇₋₂₆₆; SEQ
ID NO:3 --.

At page 26, line 17, strike "HBV", and substitute therefor -- HCV --.

At page 36, lines 7-8, strike "tripalmitoyl-S-glycerylcysteinyl-seryl-serine" and
substitute therefor -- tripalmitoyl-S-glycerylcysteinyl-seryl-serine --.

At page 36, line 36, strike "•1985" and substitute therefor -- 1985 --.

At page 38, line 31, strike "injection" and substitute therefor -- injection --.

At page 39, line 21, strike "SEQ ID NO:55" and substitute therefor -- E1₂₅₇₋₂₆₆; SEQ
ID NO:3 --.

At page 39, line 28, strike "nucleocapside-encoded" and substitute therefor
-- nucleocapsid-encoded --.

At page 44, line 9, strike "stimulation. Falk" and substitute therefor -- stimulation, as
described by Falk --. (nc)

At page 46, line 15, strike the line.

At page 49, line 10, strike "Ma" and substitute therefor -- MA --.

At page 58, line 4, strike "activity (is)" and substitute therefor -- activity is (nc)

At page 59, line 6, strike "Aichele," and substitute therefor -- Aichele (nc)

IN THE CLAIMS:

Please cancel all currently pending claims, namely claims 10-19 and 21, without
prejudice.

Please add the following claims:

22. An isolated peptide that induces an hepatitis C virus (HCV)-specific response
in cytotoxic T lymphocytes having a sequence that differs no more than about 20% from
ADLMGYIPLV (Core₁₃₁₋₁₄₀; SEQ ID NO:1), DLMGYIPLV (Core₁₃₂₋₁₄₀; SEQ ID NO:54),
LLALLSCLTV (Core₁₇₈₋₁₈₇; SEQ ID NO:2), QLRRHIDLLV (E1₂₅₇₋₂₆₆; SEQ ID NO:3),
LLCPAGHAV (NS₃₁₁₆₉₋₁₁₇₇; SEQ ID NO:26), KLVALGINAV (NS₃₁₄₀₆₋₁₄₁₅; SEQ ID